<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984343</url>
  </required_header>
  <id_info>
    <org_study_id>21-02023315</org_study_id>
    <nct_id>NCT04984343</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer</brief_title>
  <acronym>FORT</acronym>
  <official_title>Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Viewray Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Progenics/Lantheus Pharmaceuticals, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation&#xD;
      therapy treatments in men with low or intermediate-risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized non-inferiority trial comparing 5 to 2 radiotherapy treatments&#xD;
      using an MRI linear accelerator for men with low or intermediate-risk prostate cancer&#xD;
      electing for definitive radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of patient-reported GI symptoms using the Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The primary objective is to demonstrate that 2 treatments of radiotherapy does not significantly increase patient-reported Gastrointestinal (GI) and Genitourinary (GU) symptoms compared to 5 treatments of radiotherapy 2 years after treatment completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the number of patient reported GI symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Baseline, 1 week , 3months, 6 months, 12 months and 60 months</time_frame>
    <description>Compare patient-reported GI symptoms using the EPIC at end of RT and 3, 6, 12, and 60 months from end of treatment.&#xD;
Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.&#xD;
Adverse events can be unexpected or expected, related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of patient reported GU symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Baseline, 1 week, 3months, 6 months, 12 months and 60 months</time_frame>
    <description>Compare patient-reported GU symptoms using the EPIC at end of RT and 3, 6, 12, and 60 months from end of treatment.&#xD;
Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.&#xD;
Adverse events can be unexpected or expected, related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of patient reported sexual symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Baseline, 1 week, 3months, 6 months, 12 months and 60 months</time_frame>
    <description>Compare patient-reported sexual symptoms using the EPIC at end of RT and 3, 6, 12, 24, and 60 months from end of treatment.&#xD;
Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.&#xD;
Adverse events can be unexpected or expected, related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>3 months</time_frame>
    <description>Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>6 months</time_frame>
    <description>Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>12 months</time_frame>
    <description>Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>60 months</time_frame>
    <description>Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Overall Survival Rates</measure>
    <time_frame>3 months</time_frame>
    <description>Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Overall Survival Rates</measure>
    <time_frame>6 months</time_frame>
    <description>Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Overall Survival Rates</measure>
    <time_frame>12 months</time_frame>
    <description>Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Overall Survival Rates</measure>
    <time_frame>60 months</time_frame>
    <description>Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer specific survival</measure>
    <time_frame>3 months</time_frame>
    <description>compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer specific survival</measure>
    <time_frame>6 months</time_frame>
    <description>compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer specific survival</measure>
    <time_frame>12 months</time_frame>
    <description>compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer specific survival</measure>
    <time_frame>60 months</time_frame>
    <description>compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>5 radiation treatments - ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 radiation treatments - ARM 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.&#xD;
After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.&#xD;
Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have &gt;72 hours between beginning of each fraction.</description>
    <arm_group_label>2 radiation treatments - ARM 2</arm_group_label>
    <arm_group_label>5 radiation treatments - ARM 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged &gt;=18 with histologically confirmed low or intermediate risk prostate cancer&#xD;
             per NCCN guidelines. Low risk subjects per NCCN guidelines require a high risk&#xD;
             Decipher score (â‰¥0.60).&#xD;
&#xD;
          -  ECOG 0 - 1&#xD;
&#xD;
          -  IPSS &lt; 18&#xD;
&#xD;
          -  Ability to receive MRI-guided radiotherapy.&#xD;
&#xD;
          -  Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.&#xD;
&#xD;
          -  Patients with a prior or concurrent disease whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial. Note: Any patient with a cancer&#xD;
             (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle&#xD;
             invasive bladder cancer) who has been disease-free for less than 3 years must contact&#xD;
             the Principal Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of receiving pelvic radiotherapy.&#xD;
&#xD;
          -  Patient with history of inflammatory bowel disease.&#xD;
&#xD;
          -  Unilateral or bilateral hip replacements.&#xD;
&#xD;
          -  History of bladder neck or urethral stricture.&#xD;
&#xD;
          -  TURP &lt; 6 months prior to radiotherapy&#xD;
&#xD;
          -  Metastatic (pelvic nodal or distant) disease on CT, Bone, Fluciclovine, and/or PSMA&#xD;
             PET scan&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Himanshu Nagar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pragya Yadav, Ph.D</last_name>
    <phone>6469622196</phone>
    <email>pry2003@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharanya Chandrasekhar, M.S.</last_name>
    <phone>6469623110</phone>
    <email>shc2043@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sharanya Chandrasekhar, M.S.</last_name>
      <phone>646-962-2196</phone>
      <email>shc2043@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pragya Yadav, Ph.D.</last_name>
      <phone>646-962-2199</phone>
      <email>pry2003@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Himanshu Nagar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low or intermediate risk prostate cancer</keyword>
  <keyword>Definitive radiotherapy</keyword>
  <keyword>MRI Linear accelerator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

